Me is in trouble. Once a hot Silicon Valley startup, the genetic testing company has been in free fall since a major data ...

Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Fresenius Kabi and Formycon have won US Food and Drug Administration (FDA) approval for Otulfi (ustekinumab-aauz), a ...

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations early in treatment were linked to greater probability of sustained remission.

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...

As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near ...

Plus: Adam Frisch and Jeff Hurd debate for a second time. State-level super PAC spending on legislative races.

“I am excited to join Aligos at this critical time in the Company’s growth, given the significant potential of its clinical stage therapeutics,” stated David Perry, Vice President, Business ...

New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...